Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
EJNMMI Research|January 22, 2016
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotateHo Sze Chan, Mark W Konijnenberg, Erik de Blois, et al.
Biomaterials|October 29, 2020
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of PrincipleJavad Garousi, Emma von Witting, Jesper Borin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 9, 2009
Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumoursMarleen Melis, Magda Bijster, Monique de Visser, et al.
EJNMMI Research|June 28, 2015
Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amountMark W Konijnenberg, Wout A P Breeman, Erik de Blois, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancerBart de Keizer, Anne Hoekstra, Mark W Konijnenberg, et al.
Clinical Nuclear Medicine|October 14, 2015
Localization of Radiolabeled Somatostatin Analogs in the SpleenMarleen Melis, Daniel Kaemmerer, Jan de Swart, et al.
EJNMMI Radiopharmacy and Chemistry|March 23, 2018
Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyHo Sze Chan, Erik de Blois, Mark W Konijnenberg, et al.
Journal of Translational Medicine|March 19, 2022
Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection researchSophie Bockhold, Shane J Foley, Louise A Rainford, et al.
EJNMMI Research|November 23, 2016
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysineHo Sze Chan, Mark W Konijnenberg, Tamara Daniels, et al.
International Journal of Cancer|May 12, 2019
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26Bogdan Mitran, Sara S Rinne, Mark W Konijnenberg, et al.
Pageof 7